Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 0283002 approvals

HLB Co.,LTD.

Official website

Multi-business group in healthcare, biotech, and shipbuilding, developing the oral anticancer drug rivoceranib and the cholangiocarcinoma therapy RLY-4008.

As of 2026-10-08, HLB Co.,LTD. has 2 US FDA clearances/approvals on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1985 and listed on KOSDAQ in 1996, the company operates three business segments: healthcare, biotech, and shipbuilding. In biotech, it holds the oral angiogenesis-inhibiting TKI rivoceranib and the cholangiocarcinoma drug RLY-4008 (lirafugratinib) licensed from Relay Therapeutics. Rivoceranib's NDA was submitted to the US FDA in May 2023, and the company acquired its global ex-China patent rights from Advenchen Laboratories for USD 22M and its China patent rights from SFFT Developing for USD 20M, both in September 2020.

Products & technology

  • body care deviceMedia-commerce consumer product
  • plant-based melatonin ODFMedia-commerce consumer product

Regulatory approvals

openFDA

1 US FDA drug approvals · 2026 / 1 US FDA 510(k) · 2025

  • FDA drugSubsidiary: Elevar Therapeutics, Inc.LYRFIGTU2026-09-23
    FDA drug approval · NDANDA220425
  • FDASterilized Eol Auto Lancet; Sterilized Eol Lancet Plus2025-01-13
    510(k) · TraditionalGeneral, Plastic SurgeryK243533

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

리보세라닙(Rivoceranib) · 간세포암 1차 치료(캄렐리주맙 병용) · 임상3상 결과 발표, FDA NDA 제출 · Oral TKI targeting angiogenesis; Phase 3 results for 1st-line hepatocellular carcinoma (with camrelizumab) announced Sep 2022; FDA NDA submitted May 2023; final results presented at ASCO Jun 2024

RLY-4008(리라푸그라티닉) · 담관암 · 라이선스 도입, 혁신신약 지정 · Global exclusive license-in from Relay Therapeutics in Dec 2024; granted Breakthrough Therapy designation

Key disclosures

KRX KIND via OpenDART

Patents

KIPRIS · applicant-matched
Show 26 more patents

AI reads

MAA server logs · IP-verified
44
Times AI engines pulled HLB Co.,LTD.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

2
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

42
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

7
live 0
Last 7 days
35
live 2
Last 30 days
44
live 2
All time
  • OpenAIChatGPT-Userlive2
  • OpenAIOAI-SearchBot33
  • GoogleGoogleOther3
  • PerplexityPerplexityBot2
  • MicrosoftBingbot2
  • AnthropicClaudeBot2

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 7, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for HLB Co.,LTD. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition